Suppr超能文献

兔角膜中 BMP7 和 HGF 基因过表达的长期安全性和耐受性。

Long-Term Safety and Tolerability of BMP7 and HGF Gene Overexpression in Rabbit Cornea.

机构信息

Harry S. Truman Memorial Veterans' Hospital, Columbia, MO, USA.

One-Health Vision Research Program, Departments of Ophthalmology and Biomedical Sciences, College of Veterinary Medicine, University of Missouri, Columbia, MO, USA.

出版信息

Transl Vis Sci Technol. 2021 Aug 12;10(10):6. doi: 10.1167/tvst.10.10.6.

Abstract

PURPOSE

Tissue-targeted localized BMP7+HGF genes delivered into the stroma via nanoparticle effectively treats corneal fibrosis and rehabilitates transparency in vivo without acute toxicity. This study evaluated the long-term safety and tolerability of BMP7+HGF nanomedicine for the eye in vivo.

METHODS

One eye each of 36 rabbits received balanced salt solution (group 1, naïve; n = 12), naked vector with polyethylenimine-conjugated gold nanoparticles (PEI2-GNP; group 2, naked-vector; n = 12), or BMP7+HGF genes with PEI2-GNP (group 3, BMP7+HGF; n = 12) via a topical delivery technique. Safety and tolerability measurements were performed by clinical biomicroscopy in live rabbits at predetermined time intervals up to 7 months. Corneal tissues were collected at 2 months and 7 months after treatment and subjected to histology, immunofluorescence, and quantitative real-time PCR analyses.

RESULTS

Clinical ophthalmic examinations and modified MacDonald-Shadduck scores showed no significant changes in corneal thickness (P = 0.3389), tear flow (P = 0.2121), intraocular pressure (P = 0.9958), epithelial abrasion, or ocular abnormality. Slit-lamp, stereo, confocal, and specular biomicroscopy showed no signs of blepharospasm chemosis, erythema, epiphora, abnormal ocular discharge, or changes in epithelium, stroma, and endothelium after BMP7+HGF therapy for up to 7 months, as compared with control groups. Throughout the 7-month period, no significant changes were recorded in endothelial density (P = 0.9581). Histological and molecular data were well corroborated with the subjective clinical analyses and showed no differences in the naïve, naked-vector, and BMP7+HGF groups.

CONCLUSIONS

Localized BMP7+HGF therapy is a safe, tolerable, and innovative modality for the treatment of corneal fibrosis.

TRANSLATIONAL RELEVANCE

Nanoparticle-mediated BMP7+HGF combination gene therapy has the potential to treat corneal fibrosis in vivo without short- or long-term toxicity.

摘要

目的

通过纳米粒子将组织靶向的局部 BMP7+HGF 基因递送至基质中,可有效治疗角膜纤维化,并在体内恢复透明度而无急性毒性。本研究评估了 BMP7+HGF 纳米药物在体内治疗眼睛的长期安全性和耐受性。

方法

36 只兔子的每只眼睛分别接受平衡盐溶液(第 1 组,未处理;n = 12)、与聚乙二胺缀合的金纳米粒子的裸载体(第 2 组,裸载体;n = 12)或与聚乙二胺缀合的金纳米粒子的 BMP7+HGF 基因(第 3 组,BMP7+HGF;n = 12),通过局部递送技术给药。在长达 7 个月的预定时间间隔内,通过活体兔子的临床生物显微镜检查进行安全性和耐受性测量。在治疗后 2 个月和 7 个月收集角膜组织,并进行组织学、免疫荧光和实时定量 PCR 分析。

结果

临床眼科检查和改良 MacDonald-Shadduck 评分显示,角膜厚度(P = 0.3389)、泪液流量(P = 0.2121)、眼内压(P = 0.9958)、上皮擦伤或眼部异常均无显著变化。裂隙灯、立体、共聚焦和镜面生物显微镜检查显示,与对照组相比,BMP7+HGF 治疗长达 7 个月后,无睑痉挛、红肿、溢泪、异常眼分泌物或上皮、基质和内皮改变的迹象。在 7 个月的时间内,内皮密度无明显变化(P = 0.9581)。组织学和分子数据与主观临床分析很好地吻合,未处理、裸载体和 BMP7+HGF 组之间无差异。

结论

局部 BMP7+HGF 治疗是治疗角膜纤维化的一种安全、耐受和创新的方法。

翻译

侯仁祥

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9134/8362627/9eef6459219a/tvst-10-10-6-f001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验